UNSPSC 51294510: Omiloxetine

This classification denotes an antidepressant agent with the molecular formula C27H25F2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, H8YI0SSF7B chemically known as 4'-fluoro-2-(trans-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidino)acetophenone but generally known as omiloxetine, which bears US NIH Compound Identifier 3047803. European Medicines Agency schedules Omiloxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09441MIG.

UNSPSC 51294510 Omiloxetine, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The single recent opportunity on record—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026—solicits naloxone and safe drug deactivation systems, which are harm-reduction and emergency-response products distinct from omiloxetine, a selective serotonin reuptake inhibitor used in psychiatric treatment. The code shows no current relevant activity in state and local procurement markets.

The Seminole County solicitation, issued as an IFB with a due date of July 26, 2023, requested 1,900 units of naloxone and 800 safe drug deactivation systems annually for delivery to the Seminole County Community Health Building in Sanford, Florida, with quarterly shipments and a two-year initial contract term plus one-year renewal option. Bidders were required to submit bids electronically, provide unit costs, maintain workers' compensation and liability insurance, comply with E-Verify requirements, and meet potential FEMA compliance obligations. This procurement does not represent a market for omiloxetine itself, and no additional state or local opportunities under this code have posted recently. The mismatch between the code's nominal scope and the actual procurement tagged to it suggests either a data classification error or minimal recent demand for omiloxetine through state and local procurement channels.